RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group - Gilde Healthcare

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

19. Januar 2021

Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group.

Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in and around Lahnstein and provide imaging services to several local hospitals.

RAD-x is pleased to see its Partnership model confirmed by the integration of RZL and expects to further accelerate the growth of its platform structure in 2021.

 

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over $1.5 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova...
9. Oktober 2024

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate...
7. Oktober 2024

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOANALYSIS CAPABILITIES IN DRUG DEVELOPMENT

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning...
3. Oktober 2024